LA TERAPIA DELLA SINDROME EMORRAGICA DA CARENZA DI FATTORE V = LE TRAITEMENT DU SYNDROME HEMORRAGIQUE PAR CARENCE EN FACTEUR VMARIANI G; DE ROSSI G; TRIBALTO M et al.1971; HAEMATOLOGICA; ITAL.; DA. 1971; VOL. 56; NO 9-10; PP. 430-433; ABS. ANGL.; BIBL. 5 REF.Serial Issue

PRELIMINARY RESULTS OF THE COMBINATION METHOTREXATE-ASPARAGINASE IN PATIENTS WITH ACUTE NON LYMPHOID LEUKEMIAMANDELLI F; AMADORI S; PACILLI L et al.1978; BIOMEDICINE; FRA; DA. 1978; VOL. 29; NO 4; PP. 116-117; ABS. FRE; BIBL. 5 REF.Article

THE EXPANDING SPECTRUM OF CLINICAL AND LABORATORY FEATURES OF IGE MYELOMA (REPORT OF A CASE AND REVIEW OF THE LITERATURE)DAMMACO F; MIGLIETTA A; TRIBALTO M et al.1980; RIC. CLIN. LAB.; ISSN 0390-5748; ITA; DA. 1980; VOL. 10; NO 4; PP. 583-590; BIBL. 25 REF.Article

IMMUNOLOGICAL REBOUND FOLLOWING CESSATION OF CHEMOTHERAPY IN 15 ACUTE LYMPHOID LEUKEMIA PATIENTS IN COMPLETE REMISSION.DE ROSSI G; TRIBALTO M; MONARCA B et al.1978; BIOMEDICINE; FR.; DA. 1978; VOL. 29; NO 1; PP. 11-13; ABS. FR.; BIBL. 6 REF.Article

SEQUENTIAL COMBINATION OF METHOTREXATE AND L-ASPARAGINASE IN THE TREATMENT OF REFRACTORY ACUTE LEUKEMIAAMADORI S; TRIBALTO M; PACILLI L et al.1980; CANCER TREATM. REP.; USA; DA. 1980; VOL. 64; NO 8-9; PP. 939-942; BIBL. 18 REF.Article

ALL-TRANS Retinoic acid plus low doses of cytarabine for the treatment of poor-risk acute myeloid leukemiasVENDITTI, A; STASI, R; PAPA, G et al.Annals of hematology (Print). 1993, Vol 66, Num 2, pp 59-60, issn 0939-5555Conference Paper

High interleukin-6 plasma levels in acute promyelocytic leukemiaSTASI, R; VENDITTI, A; DEL POETA, G et al.Annals of hematology (Print). 1992, Vol 64, Num 6, pp 303-304, issn 0939-5555Article

MULTIPLE MYELOMA AND RELATED CONDITIONS: AN IMMUNOPEROXIDASE STUDY OF PARAFFIN-EMBEDDED BONE MARROW BIOPSIESMARTELLI MF; FALINI B; TABILIO A et al.1982; HAEMOTOLOGICA (ROMA); ISSN 0390-6078; ITA; DA. 1982; VOL. 67; NO 1; PP. 1-16; ABS. ITA; BIBL. 47 REF.Article

VALUTAZIONE IMMUNOLOGICA IN PAZIENTI AFFETTI DA MORBO DI HODGKIN IN REMISSIONE COMPLETA E DOPO LA SOSPENSIONE DELLA TERAPIA = EXPLORATION IMMUNOLOGIQUE CHEZ LES MALADES ATTEINTS DE MALADIE DE HODGKIN EN REMISSION COMPLETE ET APRES SUSPENSION DU TRAITEMENTDE ROSSI G; PAPA G; TRIBALTO M et al.1979; FOLIA ALLERGOL. IMMUNOL. CLIN.; ITA; DA. 1979; VOL. 26; NO 3; PP. 178-184; ABS. ENG; BIBL. 26 REF.Article

FISH analysis for CML monitoring ?COX FRONCILLO, M. C; MAFFEI, L; CANTONETTI, M et al.Annals of hematology (Print). 1996, Vol 73, Num 3, pp 113-119, issn 0939-5555Article

All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemiaVENDITTI, A; STASI, R; SIMONE, M. D et al.Leukemia. 1995, Vol 9, Num 7, pp 1121-1125, issn 0887-6924Article

Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathiesBOCCADORO, M; DURIE, B. G. M; PILERI, A et al.Acta haematologica. 1987, Vol 78, Num 4, pp 239-242, issn 0001-5792Article

A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromesVENDITTI, A; TAMBURINI, A; AMADORI, S et al.Annals of hematology (Print). 2000, Vol 79, Num 3, pp 138-142, issn 0939-5555Article

Conventional induction treatments do not influence overall survival in multiple myelomaBOCCADORO, M; PALUMBO, A; MUSTO, P et al.British journal of haematology. 1997, Vol 96, Num 2, pp 333-337, issn 0007-1048Article

trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (MO)COX-FRONCILLO, M. C; ZOLLINO, M; DEL POETA, G et al.Cancer genetics and cytogenetics. 1995, Vol 80, Num 1, pp 66-67, issn 0165-4608Article

Surface markers and cytotoxic activities of lymphocytes in monoclonal gammopathy of undetermined significance and untreated multiple myeloma: increased phytohemagglutinin-induced cellular cytotoxicity and inverted helper/suppressor cell ratio are features common to both diseasesDE ROSSI, G; DE SANCTIS, G; BOTTARI, V et al.Cancer immunology and immunotherapy. 1987, Vol 25, Num 2, pp 133-136, issn 0340-7004Article

Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma : an Italian multicenter studyTRIBALTO, M; AMADORI, S; SICA, S et al.Haematologica (Roma). 2000, Vol 85, Num 1, pp 52-58, issn 0390-6078Article

Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation : analysis of 40 casesADORNO, G; BRUNO, A; ARACO, P et al.Clinical and laboratory haematology. 1998, Vol 20, Num 6, pp 341-343, issn 0141-9854Article

Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemiaDEL POETA, G; STASI, R; PAPA, G et al.Blood. 1996, Vol 87, Num 5, pp 1997-2004, issn 0006-4971Article

Minimally differentiated acute myeloid leukemia (AML-MO) : a distinct clinico-biologic entity with poor prognosisAMADORI, S; VENDITTI, A; SIMONE, M. D et al.Annals of hematology (Print). 1996, Vol 72, Num 4, pp 208-215, issn 0939-5555Article

Minimally differentiated acute myeloid leukaemia (AML-MO) : cytochemical, immunophenotypic and cytogenetic analysis of 19 casesVENDITTI, A; DEL POETA, G; PAPA, G et al.British journal of haematology. 1994, Vol 88, Num 4, pp 784-793, issn 0007-1048Article

Multiple myeloma : VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patientsBOCCADORO, M; MARMONT, F; FRIERI, R et al.Journal of clinical oncology. 1991, Vol 9, Num 3, pp 444-448, issn 0732-183XArticle

Treatment of multiple myeloma: a randomized study of three different regimensTRIBALTO, M; AMADORI, S; LEONI, P et al.Leukemia research. 1985, Vol 9, Num 8, pp 1043-1049, issn 0145-2126Article

Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapyBOCCADORO, M; GAVAROTTI, P; AMADORI, S et al.British journal of haematology. 1984, Vol 58, Num 4, pp 689-696, issn 0007-1048Article